[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"muscle-relaxants\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:muscle-relaxants":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,45,68],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":17,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":29,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":34,"lastUpdatePostDateStruct":35,"startDateStruct":38,"completionDateStruct":40,"leadSponsor":42,"locationsCount":4},"100605878","phase-4-developing-a-physiology-pharmacodynamic-model-of-rocuronium-dose-and-cardiac-output-to-investigate-the-onset-time-of-neuromuscular-relaxation-100605878",false,"NCT07168252","Developing a Physiology-Pharmacodynamic Model of Rocuronium Dose and Cardiac Output to Investigate the Onset Time of Neuromuscular Relaxation","Inclusion Criteria:\n\n* General anaesthesia utilising an arterial line and rocuronium at an approved study site hospital (WSLHD - Blacktown \\& Mount Druitt hospitals)\n* Expected procedure duration \\>1.5 hours\n* no contraindications to rocuronium neuromuscular blockade\n* no contraindications to propofol TCI anaesthesia\n\nExclusion Criteria:\n\n* Unable to consent for themselves for procedure\n* Need for hospital interpreter (not currently funded for research use)\n* pregnancy or lactation\n* BMI \\> 50\n* neuromuscular condition (e.g. affecting muscle or neuromuscular junction)\n* renal failure (eGFR \\\u003C30)\n* chronic liver failure diagnosis\n* epilepsy or antiepileptics\n* lithium\n* Atrial Fibrillation\u002FAflutter (regular rhythm needed for cardiac output monitor)\n* gentamicin administered before induction","ALL","18 Years","65 Years",{"count":19,"type":20},32,"ESTIMATED","INTERVENTIONAL",[23],"PHASE4","After a patient is put to sleep, a breathing tube is often placed through the larynx (voice box) into the trachea (windpipe). To place a breathing tube requires the muscles of the jaw, voice box, and diaphragm to be relaxed. This relaxation is usually done with muscle relaxant drugs and called paralysis. Which paralysis drug and what dose should be used has been the subject of many studies.\n\nIn certain situations it is important for the patient to be fully paralysed before being intubated. Trying to intubate a partially paralysed person may result in coughing that could spread aerosols (e.g. COVID-19), patient desaturation (dropping oxygen levels), greater physiological response to intubation (heart rate, blood pressure and intra-cranial pressure rises) as well as expose the patient to risk of harm through repeated intubation attempts.\n\nCurrent standard practice for patients needing critical care is to use the drug rocuronium at 1-1.2 mg\u002Fkg and wait 60 seconds for paralysis to occur. Unfortunately, 1.2mg\u002Fkg rocuronium often fails to provide good intubating conditions at 60s in some patients. The early studies revealed that 1 mg\u002Fkg rocuronium paralysis at 60s to be 'adequate' rather than 'excellent', as judged by those doing the intubation. One suggestion from 2000, was that a dose of 1.8 - 2.3 mg\u002Fkg rocuronium may be required to achieve 'excellent' intubating conditions at 60s in the vast majority of patients as is necessary clinically. The question of whether larger doses might be better has not been further investigated.\n\nOne of the reasons that the paralysis does not seem to work as fast in some patients may be related to the speed with which the drug travels round the body, pumped around the circulation, to the muscles, by the heart. This speed of circulation called cardiac output can be measured in patients at the time of injection. It may be possible to create a mathematical model for onset of paralysis by combining the information cardiac output, patient size, rocuronium dose administered, and time to paralysis. Such a model has been started by earlier researchers. The model needs further data for completion.\n\nOnce available, the model may be able to explain how fast the onset of paralysis might be in certain cardiac outputs. It might also deduce whether giving larger doses might help speed up the onset of paralysis in those patients.",[26,27,28],"Induction of Anaesthesia","Muscle Relaxants","Rocuronium",[30,31,32],"rocuronium","muscle relaxants","intubation","NOT_YET_RECRUITING","2025-11-21",{"date":36,"type":37},"2025-11-25","ACTUAL",{"date":39,"type":20},"2025-12-01",{"date":41,"type":20},"2026-12-31",{"name":43,"class":44},"Clare Hayes-Bradley","OTHER",{"id":46,"slug":47,"hasResults":11,"nctId":48,"briefTitle":49,"officialTitle":50,"acronym":4,"eligibilityCriteria":51,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":17,"enrollmentInfo":52,"targetDuration":4,"studyType":54,"phases":4,"briefSummary":55,"conditions":56,"keywords":4,"overallStatus":57,"whyStopped":4,"lastUpdateSubmitDate":58,"lastUpdatePostDateStruct":59,"startDateStruct":61,"completionDateStruct":63,"leadSponsor":65,"locationsCount":67},"100585183","the-association-between-residual-neuromuscular-block-risk-prediction-score-and-the-train-of-four-ratio-100585183","NCT06899048","The Association Between Residual Neuromuscular Block Risk Prediction Score and the Train-of-Four Ratio","Residual Paralysis in the Post Anesthesia Care Unit: The Association Between Residual Neuromuscular Block Risk Prediction Score and the Train-of-Four Ratio. A Prospective Single-Center Open-Label Cohort Study","Inclusion Criteria:\n\n1. Age group 18-65 years old\n2. Both genders\n3. Patients with American Society of Anesthesiologist physical status classification of 1 or 2.\n\nExclusion Criteria:\n\n1. Patients who are less than 18 years old or more than 65 years old.\n2. Patients with planned scheduled recovery in the intensive care unit or if more than 10 minutes had elapsed since tracheal extubation until NMB monitoring at the PACU.\n3. Patients on medications that interfere with muscle activity.\n4. Known allergy to neuromuscular blocking agents.\n5. Pregnancy or suspected pregnancy.\n6. Neuro-muscular diseases.\n7. Patients refusing to participate in the study.",{"count":53,"type":20},91,"OBSERVATIONAL","evaluate the degree of association, and the predictive accuracy of the REPS (as a predictive tool) compared with the TOFr as a quantitative assessment tool for (rNMB) in surgical patients in the early postoperative phase. The TOFr will be measured at 0, 15, 30, 45, and 60 min after extubation.",[27],"RECRUITING","2025-03-26",{"date":60,"type":37},"2025-03-27",{"date":62,"type":37},"2024-08-01",{"date":64,"type":20},"2026-04-01",{"name":66,"class":44},"Assiut University",1,{"id":69,"slug":70,"hasResults":11,"nctId":71,"briefTitle":72,"officialTitle":72,"acronym":4,"eligibilityCriteria":73,"healthyVolunteers":74,"sex":15,"minAge":16,"maxAge":75,"enrollmentInfo":76,"targetDuration":4,"studyType":21,"phases":78,"briefSummary":80,"conditions":81,"keywords":4,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":84,"lastUpdatePostDateStruct":85,"startDateStruct":87,"completionDateStruct":89,"leadSponsor":91,"locationsCount":4},"100570578","muscle-relaxant-effect-and-safety-of-mivacurium-chloride-and-succinylcholine-for-bronchoscopy-100570578","NCT06709066","Muscle Relaxant Effect and Safety of Mivacurium Chloride and Succinylcholine for Bronchoscopy","Inclusion Criteria:\n\n1. Patients scheduled for painless bronchoscopy who require muscle relaxants during anesthesia.\n2. Aged between 18 and 60 years.\n3. Classified as Grade I-III according to the American Society of Anesthesiologists (ASA) Physical Status Classification.\n4. Patients voluntarily participate and sign an informed consent form.\n\nExclusion Criteria:\n\n1. Patients with known allergies to any of the drugs involved in the study.\n2. Patients with severe organic diseases of the brain, heart, lungs, liver, kidneys, or other major organs.\n3. Patients with intracranial hypertension, asthma, cataracts, glaucoma, or other eye diseases.\n4. Patients with myasthenia gravis, myasthenic syndrome, severe reduction or deficiency of cholinesterase, upper motor neuron injury, or upper motor neuron diseases that may cause abnormal responses to muscle relaxants.\n5. Patients who have used medications affecting neuromuscular transmission function before the procedure.\n6. Pregnant or breastfeeding patients.\n7. Patients who have experienced extensive burns, acid-base imbalance, or electrolyte disturbances within the past six months.\n8. Patients known or suspected to be homozygous for the atypical gene for plasma cholinesterase.",true,"60 Years",{"count":77,"type":20},240,[79],"NA","The goal of this clinical trial is to evaluate whether mivacurium chloride and succinylcholine can provide effective and safe muscle relaxation in adult patients aged 18-60 years undergoing bronchoscopy who require muscle relaxants during anesthesia. The main questions it aims to answer are:\n\n* Is the recovery of spontaneous breathing within 15 minutes after drug discontinuation with mivacurium chloride non-inferior to succinylcholine?\n* How do mivacurium chloride and succinylcholine compare in terms of intraoperative hemodynamics and post-operative recovery and comfort? Researchers will compare the mivacurium chloride group and the succinylcholine group to observe if mivacurium chloride can provide similar or better recovery effects compared to succinylcholine.\n\nParticipants will:\n\n* Receive either mivacurium chloride (0.14 mg\u002Fkg induction bolus + 0.5 mg\u002Fkg\u002Fh maintenance infusion) or succinylcholine (1 mg\u002Fkg induction bolus + 5 mg\u002Fkg\u002Fh maintenance infusion) as a muscle relaxant during bronchoscopy.\n* Have their vital signs, including blood pressure, oxygen saturation, and heart rate, monitored at multiple time points during the procedure.\n* Be assessed post-procedure for spontaneous breathing recovery, consciousness recovery, and time to laryngeal mask airway (LMA) removal, as well as overall comfort and satisfaction.",[82,83,27],"Anesthesia","Bronchoscopy","2024-11-26",{"date":86,"type":37},"2024-11-29",{"date":88,"type":20},"2024-11-20",{"date":90,"type":20},"2025-12-31",{"name":92,"class":44},"Peng Liang"]